The European Medicines Agency has published its assessment report for Vokanamet (canagliflozin hemihydrate with meformin hydrochloride). Vokanamet was approved by the European Commission on 23/04/2014 for use by adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:

• In patients not adequately controlled on their maximally tolerated doses of metformin alone
• In patients on their maximally tolerated doses of metformin along with other glucose lowering medicinal products including insulin, when these do not provide adequate glycaemic control
• In patients already being treated with the combination of canagliflozin and metformin as separate tablets

For more details, go to: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002656/human_med_001760.jsp&mid=WC0b01ac058001d124